Table 1.
Genotype and treatment | % SLD+ | n |
cyp-37A1(ssd9) | 100 | 109 |
cyp-37A1(ssd2) | 100 | 100 |
cyp-37A1(ok673) | 100 | 97 |
emb-8(ssd89) | 98.8 | 83 |
cyp-37A1(ssd9); daf-12(ssd155) | 0 | 62 |
cyp-37A1(ssd9); daf-12(m583) | 1.0 | 97 |
emb-8(ssd89); daf-12(m583) | 0 | 102 |
cyp-37A1(ssd9) + WT LE(1X) | 49.2 | 61 |
cyp-37A1(ssd9) + WT LE(1X)-Del | 100 | 73 |
cyp-37A1(ssd9) + cyp-37A1(ssd9) LE(1X) | 94.7 | 95 |
cyp-37A1(ssd9) + cyp-37A1(ssd9) LE(1X)-Del | 100 | 69 |
cyp-37A1(ssd9)+ DAΔ7(0.02 µM) | 79.3 | 58 |
cyp-37A1(ssd9)+ DAΔ7(0.2 µM) | 87.7 | 57 |
cyp-37A1(ssd9)+ DAΔ7(2 µM) | 55.9 | 102 |
cyp-37A1(ssd9)+ DAΔ7(0.02 µM)* | 98.4 | 63 |
cyp-37A1(ssd9)+ DAΔ7(0.2 µM)* | 95.5 | 66 |
cyp-37A1(ssd9)+ DAΔ7(2 µM)* | 90.2 | 61 |
daf-9(e1406)† | 87 | 54 |
daf-9(e1406)+ DAΔ7(0.2 µM)† | 3.4 | 58 |
daf-9(e1406)+ DAΔ7(2 µM)† | 0 | 58 |
daf-36(k114)† | 21.4 | 56 |
daf-36(k114) + DAΔ7(0.2 µM)† | 14 | 57 |
daf-36(k114) + DAΔ7(2 µM)† | 0 | 56 |
daf-12(rh274) | 100 | 54 |
din-1(dh149); daf-12(rh274) | 0 | 81 |
din-1(dh149); daf-9(e1406) | 0 | 81 |
din-1(dh149); daf-36(k114) | 0 | 87 |
din-1(dh127) cyp-37A1(ssd9) | 94.2 | 104 |
din-1(dh127) cyp-37A1(ssd9); daf-9(e1406) | 11.1 | 45 |
din-1(dh149) cyp-37A1(ssd9); daf-36(k114) | 98.5 | 66 |
All data are of L4 stage animals shifted to 30 °C for 4 h unless otherwise indicated. % SLD+, percentage of animals with supersized LDs. LE(1X), total lipid extract equivalent to 6 mg total protein. LE-Del, total lipid extract delipidated.
Scored at L3 stage.
Scored at 20 °C.